In type 2 diabetes management, which agent is preferred for patients with established cardiovascular disease to reduce major adverse events?

• A. SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefit
• B. Metformin
• C. Sulfonylureas
• D. Insulin

Answer: (A)

When managing type 2 diabetes in someone with established cardiovascular disease, the goal shifts to not only control blood sugar but also reduce cardiovascular risk. Therapies with proven cardiovascular benefit in outcome trials are preferred. SGLT2 inhibitors (like empagliflozin, canagliflozin, dapagliflozin) have shown reductions in major adverse cardiovascular events and heart failure hospitalizations. GLP-1 receptor agonists (such as liraglutide, semaglutide, dulaglutide) have also reduced MACE in high-CV-risk patients. In contrast, metformin’s CV benefits are not as clearly demonstrated in this context, while sulfonylureas and insulin do not have the same robust evidence for reducing cardiovascular events and can carry higher hypoglycemia risk. So the best choice is an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit.